Online citations, reference lists, and bibliographies.
← Back to Search

Selection Of Excipients Based On The Biopharmaceutics Classification System Of Drugs

G. Baki, S. Chaudhari, Ripal Gaudana, S. Boddu
Published 2015 · Chemistry

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Active agents have been considered the main ingredients of any therapeutic product since the early ages of formulation technology. However, the importance of the inactive ingredients has been realized during the last three decades. With the development and manufacturing of more intelligent and multifunction excipients, new ways became available for formulation technologists to increase the beneficial effects of drugs on human body. Many modern active agents have internal characteristics that significantly decrease their potential and theoretical bioavailability; however, today we have the widest variety of inactive ingredients that we can utilize in order to change these properties. The careful and educated selection of excipients might significantly influence the effect of the drugs, including hastening or delaying their onset of action, increasing their bioavailability by changing their physicochemical characteristics, and increasing their stability. In this chapter, we focus primarily on the factors determining and influencing bioavailability as well as the selection of excipients for formulating new dosage forms with enhanced therapeutic efficacy, based on the physicochemical properties of drugs. We will provide some examples from the scientific literature to demonstrate the achievements in this multidisciplinary area.
This paper references
Phase solubility techniques
T. Higuchi (1965)
[Endodontic surgery in immature tooth roots].
F. Kreter (1975)
10.1056/NEJM198110013051403
Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.
J. Lindenbaum (1981)
10.1136/gut.27.8.886
Transit of pharmaceutical dosage forms through the small intestine.
S. Davis (1986)
10.7326/0003-4819-109-6-471
Gastropathy and ketoconazole malabsorption in the acquired immunodeficiency syndrome (AIDS).
G. Lake-Bakaar (1988)
10.1002/TERA.1420440209
Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction.
S. Takeno (1991)
10.1016/0016-5085(92)91789-7
Transit through the proximal colon influences stool weight in the irritable bowel syndrome.
M. Vassallo (1992)
10.1016/0169-409X(92)90015-I
C) Means to enhance penetration
E. S. Swenson (1992)
10.1002/JPS.2600840425
Metabolism of omeprazole by gut flora in rats.
K. Watanabe (1995)
10.1016/0378-5173(95)04137-0
Effect of penetration enhancers on flurbiprofen permeation through rat skin
S. Chi (1995)
Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers.
T. Lindmark (1995)
10.1111/J.1365-2125.1995.TB04466.X
The effects of pharmaceutical excipients on small intestinal transit.
D. Adkin (1995)
10.1002/BIT.260480511
Chemical instability of protein pharmaceuticals: Mechanisms of oxidation and strategies for stabilization.
S. Li (1995)
10.1128/AAC.39.8.1671
Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole.
T. Chin (1995)
10.1016/0169-409X(96)00009-9
Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption.
L. X. Yu (1996)
10.1016/S0168-3659(96)01599-4
Modified bile acids as carriers for peptides and drugs
W. Kramer (1997)
10.1016/S0169-409X(00)00129-0
Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
C. Lipinski (1997)
10.1016/S0168-3659(97)01633-7
USP Dissolution Apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations
D. Wong (1997)
10.1016/S0928-0987(99)00076-7
The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?
H. Blume (1999)
10.1016/S0032-9592(99)00052-7
The combined effects of pH and temperature on penicillin G decomposition and its stability modeling
A. Kheirolomoom (1999)
10.2165/00003088-199936030-00004
Drug, Meal and Formulation Interactions Influencing Drug Absorption After Oral Administration
D. Fleisher (1999)
10.1016/S1388-2457(98)00081-9
Modulation of intracortical excitability for different muscles in the upper extremity: paired magnetic stimulation study with focal versus non-focal coils
T. Shimizu (1999)
10.1016/S1056-8719(00)00107-6
Drug-like properties and the causes of poor solubility and poor permeability.
C A Lipinski (2000)
10.1002/(SICI)1520-6017(200004)89:4<429::AID-JPS1>3.0.CO;2-J
Intestinal permeation enhancers.
B. Aungst (2000)
10.1016/S0939-6411(00)00076-X
Improving drug solubility for oral delivery using solid dispersions.
C. Leuner (2000)
10.1042/BA20000014
Stabilizing effect of chemical additives against oxidation of lactate dehydrogenase
M. M. Andersson (2000)
10.1016/S0378-5173(00)00344-6
Biopharmaceutics and pharmacokinetics in drug research.
R. Panchagnula (2000)
10.1016/S0378-5173(01)00794-3
Colonic metabolism of ranitidine: implications for its delivery and absorption.
A. Basit (2001)
10.1002/JPS.1127
Effect of common excipients on Caco-2 transport of low-permeability drugs.
B. Rege (2001)
10.1016/S0378-5173(01)00867-5
Processing factors in development of solid solution formulation of itraconazole for enhancement of drug dissolution and bioavailability.
S. G. Kapsi (2001)
10.1016/S1095-6433(00)00330-5
The control of gut motility.
C. Olsson (2001)
10.1016/S0378-5173(02)00018-2
Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora.
A. Basit (2002)
10.1177/00970002042006005
A Mechanistic Approach to Understanding the Factors Affecting Drug Absorption: A Review of Fundamentals
M. Martinez (2002)
10.1007/b114443
Stability of Drugs and Dosage Forms
S. Yoshioka (2002)
10.1016/S0928-0987(01)00214-7
Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.
Jichao Kang (2002)
10.1016/S0168-3659(02)00323-1
A lipophilic paclitaxel derivative incorporated in a lipid emulsion for parenteral administration.
B. Lundberg (2003)
10.1023/A:1011984216775
Dissolution Testing as a Prognostic Tool for Oral Drug Absorption: Immediate Release Dosage Forms
J. Dressman (2004)
10.1023/A:1016256619309
The Effect of Different Concentrations of Mannitol in Solution on Small Intestinal Transit: Implications for Drug Absorption
D. Adkin (2004)
10.1201/9780367801021
Photostability of Drugs and Drug Formulations
H. Tønnesen (2004)
10.1023/A:1018918907670
Effect of Sodium Acid Pyrophosphate on Ranitidine Bioavailability and Gastrointestinal Transit Time
K. Koch (2004)
10.1007/s11095-004-9004-4
Predicting Drug Disposition via Application of BCS: Transport/Absorption/ Elimination Interplay and Development of a Biopharmaceutics Drug Disposition Classification System
C. Wu (2004)
10.1023/A:1015849700421
Variation in Gastrointestinal Transit of Pharmaceutical Dosage Forms in Healthy Subjects
Alastair J. Coupe (2004)
10.1023/A:1016212804288
A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability
G. Amidon (2004)
10.1023/A:1016473601633
Biopharmaceutics Classification System: The Scientific Basis for Biowaiver Extensions
L. Yu (2004)
10.1124/DMD.32.11.1311
Hepatic microsome studies are insufficient to characterize in vivo hepatic metabolic clearance and metabolic drug-drug interactions: studies of digoxin metabolism in primary rat hepatocytes versus microsomes.
J. Lam (2004)
10.1023/A:1011992518592
Human Drug Absorption Kinetics and Comparison to Caco-2 Monolayer Permeabilities
J. Polli (2004)
10.1023/A:1016016404404
Pectin/Ethylcellulose Film Coating Formulations for Colonic Drug Delivery
Z. Wakerly (2004)
10.1023/A:1007576713216
A Comparison of the Solubility of Danazol in Human and Simulated Gastrointestinal Fluids
B. L. Pedersen (2004)
10.1016/J.EJPB.2005.03.002
Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds.
M. Vertzoni (2005)
10.1016/J.EJPS.2004.12.010
Amphiphilic amino acid copolymers as stabilizers for the preparation of nanocrystal dispersion.
J. Lee (2005)
10.1007/BF01061761
The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon
R. Oberle (2005)
10.1211/0022357055263
The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension
H. Lennernäs (2005)
10.1016/J.FARMAC.2005.08.007
In situ and in vivo efficacy of peroral absorption enhancers in rats and correlation to in vitro mechanistic studies.
P. Sharma (2005)
10.5414/CPP44071
Effect of erythromycin on the absorption of fexofenadine in the jejunum, ileum and colon determined using local intubation in healthy volunteers.
N. Petri (2006)
10.1002/JPS.20434
Transport of levovirin prodrugs in the human intestinal Caco-2 cell line.
Fujun Li (2006)
10.1021/MP0600182
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan.
T. Takagi (2006)
10.1007/s11095-006-9041-2
Why is it Challenging to Predict Intestinal Drug Absorption and Oral Bioavailability in Human Using Rat Model
X. Cao (2006)
10.1016/J.EJPB.2006.07.009
Application of sucrose fatty acid esters in transdermal therapeutic systems.
G. Csóka (2007)
10.1177/0091270007299930
Nuclear Receptors and the Regulation of Drug‐Metabolizing Enzymes and Drug Transporters: Implications for Interindividual Variability in Response to Drugs
B. Urquhart (2007)
10.1021/MP070028I
Biopharmaceutics classification of selected beta-blockers: solubility and permeability class membership.
Y. Yang (2007)
10.1016/J.ADDR.2007.08.017
The effects of pharmaceutical excipients on drug disposition.
Talia R Buggins (2007)
10.1124/dmd.106.014217
Improvement of the Oral Drug Absorption of Topotecan through the Inhibition of Intestinal Xenobiotic Efflux Transporter, Breast Cancer Resistance Protein, by Excipients
T. Yamagata (2007)
Aulton's pharmaceutics: the design and manufacture of medicines
Me Aulton (2007)
10.1007/s11095-007-9523-x
The Use of BDDCS in Classifying the Permeability of Marketed Drugs
L. Benet (2007)
10.1016/J.JCONREL.2007.08.021
Effect of excipients on breast cancer resistance protein substrate uptake activity.
T. Yamagata (2007)
10.1128/JB.00239-07
Low Concentrations of Bile Salts Induce Stress Responses and Reduce Motility in Bacillus cereus ATCC 14570
Simen M Kristoffersen (2007)
10.1208/ps040440
An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine
B. Johnson (2008)
10.1208/s12248-008-9040-9
Summary Workshop Report: Bioequivalence, Biopharmaceutics Classification System, and Beyond
J. Polli (2008)
10.1208/s12248-008-9020-0
Use of the Biopharmaceutical Classification System in Early Drug Development
M. S. Ku (2008)
10.1016/J.IJPHARM.2007.06.018
A critical evaluation of fasted state simulating gastric fluid (FaSSGF) that contains sodium lauryl sulfate and proposal of a modified recipe.
A. Aburub (2008)
10.1002/jps.21271
An investigation into the digestion of chitosan (noncrosslinked and crosslinked) by human colonic bacteria.
E. McConnell (2008)
10.1007/978-0-387-74901-3
Drug Absorption Studies
C. Ehrhardt (2008)
10.1016/j.ijpharm.2008.05.012
Gut instincts: explorations in intestinal physiology and drug delivery.
E. McConnell (2008)
10.1208/s12248-008-9036-5
Application of the Biopharmaceutical Classification System in Clinical Drug Development—An Industrial View
J. Cook (2008)
10.1208/s12248-008-9027-6
In Vitro Studies are Sometimes Better than Conventional Human Pharmacokinetic In Vivo Studies in Assessing Bioequivalence of Immediate-Release Solid Oral Dosage Forms
J. Polli (2008)
10.1208/ps010203
Prediction of dissolution-absorption relationships from a continuous dissolution/Caco-2 system
M. Ginski (2008)
10.1021/mp8001864
The use of drug metabolism for prediction of intestinal permeability (dagger).
M. Chen (2009)
10.1007/s11095-009-9924-0
The Role of Transporters in the Pharmacokinetics of Orally Administered Drugs
S. Shugarts (2009)
10.1021/mp800122b
Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay.
Victoria E Thiel-Demby (2009)
10.1208/s12248-009-9144-x
Prediction of Solubility and Permeability Class Membership: Provisional BCS Classification of the World’s Top Oral Drugs
A. Dahan (2009)
10.1152/ajpgi.00102.2009
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.
A. Dahan (2009)
10.1021/mp800128y
Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation.
I. Kovacevic (2009)
10.1063/1.3453713
Molecular basis for polyol-induced protein stability revealed by molecular dynamics simulations.
Fu-feng Liu (2010)
10.1016/j.ejps.2010.05.002
Intestinal permeability enhancement of levothyroxine sodium by straight chain fatty acids studied in MDCK epithelial cell line.
Dimple Pabla (2010)
10.1002/jps.21903
Solubility advantage of amorphous pharmaceuticals: I. A thermodynamic analysis.
S. Murdande (2010)
10.1007/BF03189322
Gastric juice as a dissolution medium: Surface tension and pH
M. Efentakis (2010)
10.1016/j.jconrel.2009.10.005
Impact of emulsion-based drug delivery systems on intestinal permeability and drug release kinetics.
Fulden Buyukozturk (2010)
10.1007/BF03190052
Guidances related to bioavailability and bioequivalence: European industry perspective
G. Ahr (2010)
10.4103/0250-474X.91585
Mixed Hydrotropy: Novel Science of Solubility Enhancement
R. Maheshwari (2011)
10.1016/j.jconrel.2011.07.003
Recent advances and novel strategies in pre-clinical formulation development: an overview.
Amit K Shah (2011)
10.1016/j.addr.2011.06.015
Molecular origins of surfactant-mediated stabilization of protein drugs.
H. Lee (2011)
10.1016/j.ijpharm.2011.03.033
Applicability of sucrose laurate as surfactant in solid dispersions prepared by melt technology.
A. Szűts (2011)
10.3109/03639045.2011.569933
Formulation of tablets containing an ‘in-process’ amorphized active pharmaceutical ingredient
Orsolya Jójárt-Laczkovich (2011)
10.1016/j.jpba.2011.01.024
Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes.
Á. Szabados-Nacsa (2011)
10.1016/J.CES.2012.01.046
Process-induced phase transformations in a pharmaceutically relevant salt-free form system
Haiyan Qu (2012)
10.3109/02713683.2011.631722
A Comparison of Active Ingredients and Preservatives Between Brand Name and Generic Topical Glaucoma Medications Using Liquid Chromatography-Tandem Mass Spectrometry
M. Kahook (2012)
10.3109/03639045.2012.683440
Self-nanoemulsifying drug delivery system of cefpodoxime proxetil containing tocopherol polyethylene glycol succinate
A. Bajaj (2013)
10.3109/03639045.2012.687745
Single non-ionic surfactant based self-nanoemulsifying drug delivery systems: formulation, characterization, cytotoxicity and permeability enhancement study
M. Bandivadekar (2013)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar